In vitro method for the diagnosis and/or prognosis of malignant melanoma

  • Universidad de Granada
  • From Spain
  • Responsive
  • Patents for licensing

Summary of the technology

A group of single nucleotide polymorphisms (SNPs) related to the risk and aggressiveness of malignant melanoma has been identified. Thus, an in vitro method based on these biomarkers identification is proposed for diagnosis and/or prognosis of malignant melanoma and, additionally, to determine whether these patients respond adequately to treatment.

In the same way, it has been proved with in vitro and in silico expression assays that the proposed SNPs for risk and aggressiveness of malignant melanoma are reinforced.

Universidad de Granada

Details of the Technology Offer

Malignant melanoma (MM), whose prevalence has been increasing in recent years, is the most aggressive form of skin cancer and represents the leading cause of death from skin diseases.

The intratumoral heterogeneity and the complexity of the current status of germline mutations in this type of cancer make it complex to design therapeutic strategies. In this sense, there is a medical need to find reliable biomarkers for an early diagnosis and prognosis of MM, which will facilitate adequate monitoring of the disease, a correct choice of treatment and the control of its subsequent response.

In this sense, the present invention proposes eight risk SNPs are related to melanoma, proposing them for use as biomarkers and gene signatures of this condition, aiding earlier identification and thus shortening the time to initiation of treatment.

These promising markers form the basis of the in vitro method developed that allows a diagnosis of MM in patients at risk or with signs of suffering it from a simple biological sample (skin tissue, saliva, blood, urine, serum or plasma). As well, it assesses whether patients who are being treated respond to such therapy. Thus, the presence of at least one of these SNPs: CLPTM1L (rs401681), LOC107987026 (rs1335510), TYRP1 (rs2733832), MTAP (rs7023329), TYR (rs1126809), MX2 (rs45430), CTXND2 (rs7412746) and PARP1 (rs3219090); or a high expression level in the TYRP1 and TYR genes are considered indications that the individual has MM, has a poor prognosis or is responding poorly to treatment.

Therefore, this method is an aid to improve precision medicine for MM patients and their closest relatives.


  • It enables early diagnosis of MM and its prognosis.This method and the eight risk SNPs identified facilitate earlier identification of the disease and its prognosis, thus reducing the time to initiation of treatment.
  • Assessment of response to treatment.In patients diagnosed with melanoma who are treating, the proposed method makes it possible to know whether or not the patient is responding to such therapy.
  • Improved precision medicine.The proposed in vitro method helps to be more accurate in diagnosing melanoma patients and their closest relatives, making easier the choice of the appropriate treatment for each individual.
  • The biological sample to be analyzed is easily accessible: skin tissue, saliva, blood, urine, serum or plasma.
  • No specific equipment is required. The genotyping of SNPs and the quantification of the expression levels of these biomarkers is carried out by PCR and/or qPCR, currently popular techniques, generally common and accessible in laboratories of the sector.
  • Simple method. The possibility of using a kit or device makes it easier to obtain useful data for the diagnosis and prognosis of this type of melanoma.

Intellectual property status

  • Patent already applied for
  • Patent application number :EP21382617.5

Related Keywords

  • Diagnostics, Diagnosis
  • Biological Sciences
  • Infectious Diseases
  • Genetic Engineering / Molecular Biology
  • Gene Expression, Proteom Research Market
  • melanoma
  • biomarkers
  • precision medicine
  • snp
  • expression patterns
  • single nucleotide polymorphism
  • malignant melanoma
  • clptm1l
  • tyr

About Universidad de Granada

Granada University is one of the most important universities of Spain. The main goal is to transfer technology that our research groups, more than 500, are developing to the industries and companies which are able to take profit from them. It is a general University so Research and Development are offered in different fields like Health Science and Technology, Physics, Chemistry and Mathematics, Environment and Natural Resources, Biotechnology, Information and Communication Technologies, Social, Economic and Legal Sciences....

We hope you find technologies of your interest which will allow us working together in the near future.

Universidad de Granada

Never miss an update from Universidad de Granada

Create your free account to connect with Universidad de Granada and thousands of other innovative organizations and professionals worldwide

Universidad de Granada

Send a request for information
to Universidad de Granada

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support